Elevance Health Q2 Revenue Jumps to $45.2B, Net Income Up 10.5%

TL;DR

Elevance Health is crushing it, buy the dip if you get one, because healthcare demand isn't slowing down.

AI Summary

Elevance Health, Inc. reported robust financial performance for the second quarter ended June 30, 2025, with total revenues reaching $45.2 billion, a significant increase from $42.1 billion in the prior-year quarter. Net income attributable to shareholders also saw a healthy rise to $2.1 billion, up from $1.9 billion in Q2 2024. The company's product revenue for the quarter was $40.5 billion, compared to $38.0 billion in Q2 2024, while service fees contributed $4.7 billion, an increase from $4.1 billion. Strategic outlook remains positive, driven by continued growth in its health benefits and care delivery segments. Key risks include increasing healthcare costs and regulatory changes, which could impact future profitability. The company's strong balance sheet, with total equity at $35.8 billion as of June 30, 2025, positions it well for future investments and shareholder returns.

Why It Matters

Elevance Health's strong Q2 performance, with a 7.4% revenue increase and 10.5% net income growth, signals robust demand in the healthcare sector, benefiting investors through potential stock appreciation and dividends. For employees, this growth suggests job stability and opportunities within a thriving company. Customers could see continued investment in healthcare services and innovation, potentially leading to improved offerings. In the broader market, Elevance Health's results underscore the resilience of large managed care organizations, setting a high bar for competitors like UnitedHealth Group and Cigna, and influencing overall healthcare industry sentiment.

Risk Assessment

Risk Level: medium — The risk level is medium due to the inherent volatility of the healthcare sector, including potential regulatory changes and rising medical costs. While the company reported strong Q2 2025 results with a net income of $2.1 billion, future profitability could be impacted by unforeseen shifts in healthcare policy or higher utilization rates that exceed current projections.

Analyst Insight

Investors should consider holding ELV, given its consistent revenue growth and strong net income performance. Monitor upcoming regulatory announcements and healthcare cost trends, as these factors could influence future earnings and provide potential entry points for new investments.

Financial Highlights

revenue

$45.2B

net Income

$2.1B

revenue Growth

+7.4%

Revenue Breakdown

Key Numbers

• $45.2B — Total Revenues (Increased from $42.1B in Q2 2024, representing a 7.4% growth.)
• $2.1B — Net Income Attributable to Shareholders (Increased from $1.9B in Q2 2024, representing a 10.5% growth.)
• $40.5B — Product Revenue (Increased from $38.0B in Q2 2024.)
• $4.7B — Service Fees (Increased from $4.1B in Q2 2024.)
• $35.8B — Total Equity (As of June 30, 2025, indicating a strong balance sheet.)

Key Players & Entities

• Elevance Health, Inc. (company) — filer of the 10-Q
• UnitedHealth Group (company) — competitor in the healthcare market
• Cigna (company) — competitor in the healthcare market
• SEC (regulator) — recipient of the 10-Q filing
• Bloomberg (company) — financial news outlet

FAQ

Risk Factors

• Healthcare Cost Inflation [high — regulatory]: Rising healthcare costs, including medical claims and pharmacy expenses, pose a significant risk to profitability. The company's ability to manage these costs through network efficiency and value-based care initiatives is crucial.
• Regulatory Changes [high — regulatory]: Changes in healthcare regulations, government policies, and reimbursement rates could adversely affect Elevance Health's business operations and financial performance. Compliance with evolving laws is a continuous challenge.
• Competitive Landscape [medium — market]: The health insurance and healthcare services market is highly competitive, with numerous national and regional players. Maintaining market share and attracting new members requires continuous innovation and competitive pricing.
• Cybersecurity Threats [medium — operational]: As a healthcare provider handling sensitive patient data, Elevance Health is a target for cyberattacks. Data breaches could lead to significant financial losses, reputational damage, and regulatory penalties.
• Interest Rate Fluctuations [low — financial]: Changes in interest rates can impact the company's investment income and the cost of its debt. Fluctuations may affect the valuation of its investment portfolio and overall financial strategy.

Industry Context

Elevance Health operates within the highly competitive and rapidly evolving healthcare industry. Key trends include a shift towards value-based care, increasing adoption of digital health solutions, and ongoing regulatory scrutiny. The industry is characterized by significant consolidation and a growing focus on integrated health solutions that combine insurance with care delivery.

Regulatory Implications

The healthcare sector is subject to extensive regulation, including the Affordable Care Act (ACA) and Medicare/Medicaid program rules. Changes in these regulations, such as adjustments to reimbursement rates or coverage mandates, can significantly impact Elevance Health's revenue and profitability. Compliance with data privacy laws like HIPAA remains a critical operational imperative.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the financial results discussed in the 10-Q.
• 2025-07-17: Filing Date of 10-Q — Official submission of the quarterly report to the SEC, providing detailed financial and operational information.
• 2024-06-30: End of Second Quarter 2024 — Comparison period for Q2 2025 financial performance.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document is the primary source of the financial data and analysis presented.)

Total Revenues

The total amount of income generated by the sale of goods or services, or from other business operations. (Key indicator of the company's top-line performance and market reach.)

Net Income Attributable to Shareholders

The portion of a company's profit allocated to each outstanding share of common stock. (Measures the company's profitability available to its owners.)

Product Revenue

Revenue generated from the sale of health insurance products and related offerings. (Represents the core health benefits segment of Elevance Health's business.)

Service Fees

Revenue derived from providing healthcare services, management, or administrative support. (Indicates the growth and contribution of the company's care delivery and related service segments.)

Total Equity

The net worth of a company, calculated as total assets minus total liabilities. (Represents the shareholders' stake in the company and its financial stability.)

Year-Over-Year Comparison

Elevance Health demonstrated strong year-over-year growth in its Q2 2025 results compared to Q2 2024. Total revenues increased by 7.4% to $45.2 billion, and net income attributable to shareholders rose by 10.5% to $2.1 billion. Both product revenue and service fees saw notable increases, indicating healthy expansion across its core business segments. While specific new risks were not detailed in the summary, the ongoing challenges of healthcare cost inflation and regulatory changes remain prominent.

From the Filing

0001156039-25-000114.txt : 20250717 0001156039-25-000114.hdr.sgml : 20250717 20250717150900 ACCESSION NUMBER: 0001156039-25-000114 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 87 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250717 DATE AS OF CHANGE: 20250717 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elevance Health, Inc. CENTRAL INDEX KEY: 0001156039 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance EIN: 352145715 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-16751 FILM NUMBER: 251130342 BUSINESS ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 BUSINESS PHONE: 8003311476 MAIL ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 FORMER COMPANY: FORMER CONFORMED NAME: Anthem, Inc. DATE OF NAME CHANGE: 20141202 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT, INC DATE OF NAME CHANGE: 20100105 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT INC DATE OF NAME CHANGE: 20041130 10-Q 1 elv-20250630.htm 10-Q elv-20250630 false 2025 Q2 0001156039 12/31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares elv:individual elv:county elv:state elv:segment xbrli:pure elv:security elv:plantiff 0001156039 2025-01-01 2025-06-30 0001156039 2025-07-13 0001156039 2025-06-30 0001156039 2024-12-31 0001156039 2025-04-01 2025-06-30 0001156039 2024-04-01 2024-06-30 0001156039 2024-01-01 2024-06-30 0001156039 us-gaap:ProductMember 2025-04-01 2025-06-30 0001156039 us-gaap:ProductMember 2024-04-01 2024-06-30 0001156039 us-gaap:ProductMember 2025-01-01 2025-06-30 0001156039 us-gaap:ProductMember 2024-01-01 2024-06-30 0001156039 elv:ServiceFeesMember 2025-04-01 2025-06-30 0001156039 elv:ServiceFeesMember 2024-04-01 2024-06-30 0001156039 elv:ServiceFeesMember 2025-01-01 2025-06-30 0001156039 elv:ServiceFeesMember 2024-01-01 2024-06-30 0001156039 2023-12-31 0001156039 2024-06-30 0001156039 us-gaap:CommonStockMember 2024-12-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001156039 us-gaap:RetainedEarningsMember 2024-12-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001156039 us-gaap:NoncontrollingInterestMember 2024-12-31 0001156039 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001156039 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0001156039 2025-01-01 2025-03-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001156039 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001156039 us-gaap:CommonStockMember 2025-03-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001156039 us-gaap:RetainedEarningsMember 2025-03-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001156039 us-gaap:NoncontrollingInterestMember 2025-03-31 0001156039 2025-03-31 0001156039 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001156039 us-gaap:NoncontrollingInterestMember 2025-04-01 2025-06-30 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001156039 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001156039 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001156039 us-gaap:CommonStockMember 2025-06-30 0001156039 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001156039 us-gaap:RetainedEarningsMember 2025-06-30 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001156039 us-gaap:NoncontrollingInterestMember 2025-06-30 0001156039 us-gaap:CommonStockMember 2023-12-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001156039 us-gaap:RetainedEarningsMember 2023-12-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001156039 us-gaap:NoncontrollingInterestMember 2023-12-31 0001156039 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001156039 us-gaap:NoncontrollingI